Suzhou Sepax Technologies Co Ltd is engaged in the Research, development and produce liquid chromatography materials for drug analysis, detection, separation and purification.
2009
n/a
LTM Revenue $45.4M
LTM EBITDA n/a
$964M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Sepax Technologies has a last 12-month revenue of $45.4M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Sepax Technologies achieved revenue of $33.8M and an EBITDA of $11.3M.
Sepax Technologies expects next 12-month revenue of XXX   and NTM EBITDA of XXX
See Sepax Technologies valuation multiples based on analyst estimatesFY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
---|---|---|---|---|---|
Revenue | $29.3M | $33.8M | XXX | XXX | XXX |
Gross Profit | $15.2M | $22.4M | XXX | XXX | XXX |
Gross Margin | 52% | 66% | XXX | XXX | XXX |
EBITDA | $9.6M | $11.3M | XXX | XXX | XXX |
EBITDA Margin | 33% | 33% | XXX | XXX | XXX |
Net Profit | $2.9M | $6.5M | XXX | XXX | XXX |
Net Margin | 10% | 19% | XXX | XXX | XXX |
Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Sepax Technologies's stock price is CNY 17 (or $2).
Sepax Technologies has current market cap of CNY 7.1B (or $980M), and EV of CNY 7.0B (or $964M).
See Sepax Technologies trading valuation dataEV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
---|---|---|---|---|---|---|
$964M | $980M | XXX | XXX | XXX | XXX | $0.03 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Sepax Technologies has market cap of $980M and EV of $964M.
Sepax Technologies's trades at 21.2x LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Sepax Technologies's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Sepax Technologies and 10K+ public compsFY 2024 | FY 2025E | FY 2026E | FY 2027E | |
---|---|---|---|---|
EV | $964M | XXX | XXX | XXX |
EV/Revenue | 28.5x | XXX | XXX | XXX |
EV/EBITDA | 85.5x | XXX | XXX | XXX |
P/E | 135.5x | XXX | XXX | XXX |
P/E/Growth | 2.6x | XXX | XXX | XXX |
EV/FCF | 288.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpSepax Technologies's NTM/LTM revenue growth is 22%
Sepax Technologies's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged n/a for the same period.
Over next 12 months, Sepax Technologies's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Sepax Technologies's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Sepax Technologies and other 10K+ public compsFY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
---|---|---|---|---|---|
Revenue Growth | 15% | XXX | XXX | XXX | XXX |
EBITDA Margin | 33% | XXX | XXX | XXX | XXX |
EBITDA Growth | 17% | XXX | XXX | XXX | XXX |
Rule of 40 (SaaS-only) | 55% | XXX | XXX | XXX | XXX |
Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
Opex per Employee | n/a | XXX | XXX | XXX | XXX |
S&M Expenses to Revenue | 3% | XXX | XXX | XXX | XXX |
G&A Expenses to Revenue | 6% | XXX | XXX | XXX | XXX |
R&D Expenses to Revenue | 18% | XXX | XXX | XXX | XXX |
Opex to Revenue | 49% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
EV/Revenue | EV/EBITDA | |||||
---|---|---|---|---|---|---|
2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
Zomedica | XXX | XXX | XXX | XXX | XXX | XXX |
AnteoTech | XXX | XXX | XXX | XXX | XXX | XXX |
Proteomics International | XXX | XXX | XXX | XXX | XXX | XXX |
Biohit | XXX | XXX | XXX | XXX | XXX | XXX |
Genomictree | XXX | XXX | XXX | XXX | XXX | XXX |
XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Sepax Technologies acquired XXX companies to date.
Last acquisition by Sepax Technologies was XXXXXXXX, XXXXX XXXXX XXXXXX . Sepax Technologies acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiplesAcquired Company | EV | EV/Revenue | EV/EBITDA |
---|---|---|---|
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign UpWhen was Sepax Technologies founded? | Sepax Technologies was founded in 2009. |
Where is Sepax Technologies headquartered? | Sepax Technologies is headquartered in China. |
Is Sepax Technologies publicy listed? | Yes, Sepax Technologies is a public company listed on SHG. |
What is the stock symbol of Sepax Technologies? | Sepax Technologies trades under 688758 ticker. |
When did Sepax Technologies go public? | Sepax Technologies went public in 2025. |
Who are competitors of Sepax Technologies? | Similar companies to Sepax Technologies include e.g. Zomedica, AnteoTech, Proteomics International, Biohit. |
What is the current market cap of Sepax Technologies? | Sepax Technologies's current market cap is $980M |
What is the current revenue of Sepax Technologies? | Sepax Technologies's last 12-month revenue is $45.4M. |
What is the current EV/Revenue multiple of Sepax Technologies? | Current revenue multiple of Sepax Technologies is 21.2x. |
What is the current revenue growth of Sepax Technologies? | Sepax Technologies revenue growth between 2023 and 2024 was 15%. |
Is Sepax Technologies profitable? | Yes, Sepax Technologies is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.